Life Scientist > Biotechnology

Calzada narrows FY13 loss by 45%

28 August, 2013 by Dylan Bushell-Embling

A higher R&D tax benefit in FY13 helped Calzada (ASX:CZD) narrow its loss for the FY13 financial year to $1.5m.


FDA knocks back QRxPharma's MoxDuo again

28 August, 2013 by Dylan Bushell-Embling

QRxPharma (ASX:QRL) will need to resubmit its FDA application for MoxDuo IR again, after the regulator issued a second Complete Response Letter.


A win for the health industry in the Curtin Commercial Innovation Awards

27 August, 2013

The 2013 Curtin Commercial Innovation Awards winners have been announced, with the three winning entries each having strong or potential applications in the medical industry.


Coalition pledges "new approach" to manufacturing

27 August, 2013

AusBiotech has welcomed 'The Coalition’s Policy to Boost the Competitiveness of Australian Manufacturing' with its support for a "new approach" to manufacturing and a returned focus to Australian industry and SMEs.


Allied Healthcare gets CE Mark for CardioCel

26 August, 2013 by Dylan Bushell-Embling

After securing regulatory approval, Allied Healthcare (ASX:AHZ) now expects to start selling its CardioCel heart patch in Europe in calendar Q4.


Nexvet picks up a $1.5m CA grant

23 August, 2013 by Dylan Bushell-Embling

Commercialisation Australia will award Nexvet a further $1.5m in grant funding to help the company bring its PETisation technology to market.


AusBiotech welcomes new venture capital fund for biotech

22 August, 2013

AusBiotech has commended the Labor government’s response to the Strategic Review of Health and Medical Research (The McKeon Review) and its pledge to establish the $250 million Medical Research Innovation Fund (MRIF).


iSonea wins Frost innovation award

21 August, 2013 by Dylan Bushell-Embling

Frost & Sullivan has handed iSonea (ASX:ISN) an Innovation Leadership Award for its AsthmaSense cloud mobile health-monitoring technology.


Nominations invited for 2013 Industry Excellence Awards

20 August, 2013

Janssen and AusBiotech are delighted to announce that the Janssen 2013 Industry Excellence Awards are now open for nominations. The awards, which have three categories, will be announced at AusBiotech 2013 in Brisbane on 30 October.


Prime Minister announces Medical Technologies Innovation Partnership

19 August, 2013

Prime Minister Kevin Rudd last week announced the Medical Technologies Innovation Partnership - the first of the Australian Innovation Partnership program. The program is intended to create partnerships between government, business and the research community that will create new high-skill jobs for the future.


Consultation on cost recovery for gene technology regulator

15 August, 2013

The Department of Health and Ageing (DoHA) is undertaking an assessment and development of a cost recovery model for services provided by the Office of the Gene Technology Regulator (OGTR). DoHA has engaged PricewaterhouseCoopers (PwC) to undertake an economic analysis of the gene technology sector, and PwC is seeking input from sector stakeholders through the stakeholder survey.


MDI achieves goals with Penthrox trial

14 August, 2013 by Dylan Bushell-Embling

Medical Developments International (ASX:MVP) said a safety study of its Penthrox inhaler uncovered no safety concerns associated with a single supratherapeutic dose.


CSL boosts FY13 profit by 19%

14 August, 2013 by Dylan Bushell-Embling

CSL (ASX:CSL) recorded 19% higher profit for FY13 as well as 7% higher revenue, and has announced the appointment of a new director.


Ita Buttrose to speak on philanthropy for research

13 August, 2013

Legendary media editor, businesswoman and 2013 Australian of the Year Ita Buttrose will be the guest dinner speaker at next week’s Research Australia 2013 Philanthropy for Health and Medical Research conference.


Cochlear FY13 profit recovers after recall

12 August, 2013 by Dylan Bushell-Embling

Cochlear Limited (ASX:COH) reported a net profit for FY13 of $132.6m - up 133% year on year, but down 16% when excluding the costs of a product recall in FY12.


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd